Based in Laval, Quebec, Corealis is a CDMO in the Americas for the formulation and manufacturing of solid dosage oral pharmaceutical products – tablets, capsules and granules – in pre-clinical and pre-marketing clinical trials.
“ArchiMed understood our strategy and came up with an interesting investment thesis,” said Yves Roy, President of Corealis. “We have turned down several higher offers from potential suitors – commercial and financial. Like us, ArchiMed understands the significant potential of this industry and what it takes to take it to the next level. As partners, we will be able to capitalize on market leadership, by aggressively developing our scientific strengths in R&D and our best regulatory compliant manufacturing processes. [such regulatory compliant processes are known as Good Manufacturing Practices or GMP].” Roy and fellow founders Patrick Gosselin and Yves Mouget retain a significant stake in Corealis.
“With the expertise of Corealis, the influence of CDPQ and our knowledge of the international healthcare landscape, we have the perfect combination to scale rapidly in a growing industry,” says Robin Filmer-Wilson, ArchiMed Partner . Since 2019, Corealis sales have recorded an average annual growth of more than 15%, a pace that is expected to accelerate as the outsourcing of drug formulation increases in response to inflation and more demanding regulations. . The deal was closed by ArchiMed’s Pharmaceutical Services team, aided by ArchiMed’s MedTalents®, a global network of senior healthcare executives associated with ArchiMed who identify, facilitate and advise deals and advise companies in the wallet.
MED III invests in the small cap healthcare sectors in Europe and the Americas, in partnership with owners and managers.
Fairmount Partners, a leading investment bank in the pharmaceutical services industry, served as exclusive financial advisor to Corealis.